Skip to content
2000
Volume 14, Issue 2
  • ISSN: 1871-5249
  • E-ISSN: 1875-6166

Abstract

Serotonin receptors (5-HTRs) are implicated in the pathophysiology of a variety of neuropsychiatric and neurodegenerative disorders and are also targets for drug therapy. In the CNS, most of these receptors are expressed in high abundance in specific brain regions reflecting their role in brain functions. Quantifying binding to 5-HTRs in vivo may permit assessment of physiologic and pathologic conditions, and monitoring disease progression, evaluating treatment response, and for investigating new treatment modalities. Positron emission tomography (PET) molecular imaging has the sensitivity to quantify binding of 5-HTRs in CNS disorders and to measure drug occupancy as part of a process of new drug development. Although research on PET imaging of 5-HTRs have been performed more than two decades, the successful radiotracers so far developed for human studies are limited to 5-HT1AR, 5-HT1BR, 5-HT2AR, 5-HT4R and 5-HT6R. Herein we review the development and application of radioligands for PET imaging of 5-HTRs in living brain.

Loading

Article metrics loading...

/content/journals/cnsamc/10.2174/1871524914666141030124316
2014-09-01
2025-12-24
Loading full text...

Full text loading...

/content/journals/cnsamc/10.2174/1871524914666141030124316
Loading

  • Article Type:
    Research Article
Keyword(s): 5-HTR; Molecular imaging; PET; radioligands; serotonin receptors
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test